Literature DB >> 24378367

The role of clusterin in amyloid-β-associated neurodegeneration.

Rahul S Desikan1, Wesley K Thompson2, Dominic Holland3, Christopher P Hess4, James B Brewer5, Henrik Zetterberg6, Kaj Blennow7, Ole A Andreassen8, Linda K McEvoy1, Bradley T Hyman9, Anders M Dale10.   

Abstract

IMPORTANCE: Converging evidence indicates that clusterin, a chaperone glycoprotein, influences Alzheimer disease neurodegeneration. However, the precise role of clusterin in Alzheimer disease pathogenesis is still not well understood.
OBJECTIVE: To elucidate the relationship between clusterin, amyloid-β (Aβ), phosphorylated tau (p-tau), and the rate of brain atrophy over time among nondemented older individuals. DESIGN, SETTING, AND PARTICIPANTS: This longitudinal cohort included cognitively normal older participants and individuals with mild cognitive impairment assessed with baseline lumbar puncture and longitudinal structural magnetic resonance imaging. We examined 241 nondemented older individuals from research centers across the United States and Canada (91 participants with a Clinical Dementia Rating score of 0 and 150 individuals with a Clinical Dementia Rating score of 0.5). MAIN OUTCOMES AND MEASURES: Using linear mixed-effects models, we investigated interactions between cerebrospinal fluid (CSF) clusterin, CSF Aβ1-42, and CSF p-tau at threonine 181 (p-tau181p) on the atrophy rate of the entorhinal cortex and hippocampus.
RESULTS: Across all participants, we found a significant interaction between CSF clusterin and CSF Aβ1-42 on the entorhinal cortex atrophy rate but not on the hippocampal atrophy rate. Cerebrospinal fluid clusterin was associated with the entorhinal cortex atrophy rate among CSF Aβ1-42-positive individuals but not among CSF Aβ1-42-negative individuals. In secondary analyses, we found significant interactions between CSF Aβ1-42 and CSF clusterin, as well as CSF Aβ1-42 and CSF p-tau181p, on the entorhinal cortex atrophy rate. We found similar results in subgroup analyses within the mild cognitive impairment and cognitively normal cohorts. CONCLUSIONS AND RELEVANCE: In nondemented older individuals, Aβ-associated volume loss occurs in the presence of elevated clusterin. The effect of clusterin on Aβ-associated brain atrophy is not confounded or explained by p-tau. These findings implicate a potentially important role for clusterin in the earliest stages of the Alzheimer disease neurodegenerative process and suggest independent effects of clusterin and p-tau on Aβ-associated volume loss.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24378367      PMCID: PMC4118752          DOI: 10.1001/jamaneurol.2013.4560

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN: 2168-6149            Impact factor:   18.302


  28 in total

1.  Amyloid-β associated volume loss occurs only in the presence of phospho-tau.

Authors:  Rahul S Desikan; Linda K McEvoy; Wesley K Thompson; Dominic Holland; J Cooper Roddey; Kaj Blennow; Paul S Aisen; James B Brewer; Bradley T Hyman; Anders M Dale
Journal:  Ann Neurol       Date:  2011-10-14       Impact factor: 10.422

2.  An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest.

Authors:  Rahul S Desikan; Florent Ségonne; Bruce Fischl; Brian T Quinn; Bradford C Dickerson; Deborah Blacker; Randy L Buckner; Anders M Dale; R Paul Maguire; Bradley T Hyman; Marilyn S Albert; Ronald J Killiany
Journal:  Neuroimage       Date:  2006-03-10       Impact factor: 6.556

3.  Plasma clusterin concentration is associated with longitudinal brain atrophy in mild cognitive impairment.

Authors:  Madhav Thambisetty; Yang An; Anna Kinsey; Deepthi Koka; Muzamil Saleem; Andreas Güntert; Michael Kraut; Luigi Ferrucci; Christos Davatzikos; Simon Lovestone; Susan M Resnick
Journal:  Neuroimage       Date:  2011-07-28       Impact factor: 6.556

4.  Plasma clusterin and the risk of Alzheimer disease.

Authors:  Elisabeth M C Schrijvers; Peter J Koudstaal; Albert Hofman; Monique M B Breteler
Journal:  JAMA       Date:  2011-04-06       Impact factor: 56.272

5.  Nonlinear registration of longitudinal images and measurement of change in regions of interest.

Authors:  Dominic Holland; Anders M Dale
Journal:  Med Image Anal       Date:  2011-02-23       Impact factor: 8.545

6.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.

Authors:  Leslie M Shaw; Hugo Vanderstichele; Malgorzata Knapik-Czajka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski
Journal:  Ann Neurol       Date:  2009-04       Impact factor: 10.422

7.  Structural MRI biomarkers for preclinical and mild Alzheimer's disease.

Authors:  Christine Fennema-Notestine; Donald J Hagler; Linda K McEvoy; Adam S Fleisher; Elaine H Wu; David S Karow; Anders M Dale
Journal:  Hum Brain Mapp       Date:  2009-10       Impact factor: 5.038

Review 8.  Clusterin: a forgotten player in Alzheimer's disease.

Authors:  Tapio Nuutinen; Tiina Suuronen; Anu Kauppinen; Antero Salminen
Journal:  Brain Res Rev       Date:  2009-08-03

9.  Preservation of neuronal number despite age-related cortical brain atrophy in elderly subjects without Alzheimer disease.

Authors:  Stefanie H Freeman; Ruth Kandel; Luis Cruz; Anete Rozkalne; Kathy Newell; Matthew P Frosch; E Tessa Hedley-Whyte; Joseph J Locascio; Lewis A Lipsitz; Bradley T Hyman
Journal:  J Neuropathol Exp Neurol       Date:  2008-12       Impact factor: 3.685

10.  Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease.

Authors:  Madhav Thambisetty; Andrew Simmons; Latha Velayudhan; Abdul Hye; James Campbell; Yi Zhang; Lars-Olof Wahlund; Eric Westman; Anna Kinsey; Andreas Güntert; Petroula Proitsi; John Powell; Mirsada Causevic; Richard Killick; Katie Lunnon; Steven Lynham; Martin Broadstock; Fahd Choudhry; David R Howlett; Robert J Williams; Sally I Sharp; Cathy Mitchelmore; Catherine Tunnard; Rufina Leung; Catherine Foy; Darragh O'Brien; Gerome Breen; Simon J Furney; Malcolm Ward; Iwona Kloszewska; Patrizia Mecocci; Hilkka Soininen; Magda Tsolaki; Bruno Vellas; Angela Hodges; Declan G M Murphy; Sue Parkins; Jill C Richardson; Susan M Resnick; Luigi Ferrucci; Dean F Wong; Yun Zhou; Sebastian Muehlboeck; Alan Evans; Paul T Francis; Christian Spenger; Simon Lovestone
Journal:  Arch Gen Psychiatry       Date:  2010-07
View more
  38 in total

1.  New perspectives in human tear analysis?

Authors:  Peter Kukumberg; Martin Karlík; Denisa Beňová-Liszeková; Milan Beño; Tibor Pechan; Robert Farkaš
Journal:  Neuro Endocrinol Lett       Date:  2015       Impact factor: 0.765

Review 2.  Understanding mechanisms and seeking cures for Alzheimer's disease: why we must be "extraordinarily diverse".

Authors:  Madhav Thambisetty
Journal:  Am J Physiol Cell Physiol       Date:  2017-06-14       Impact factor: 4.249

Review 3.  Therapeutic Strategies for Restoring Tau Homeostasis.

Authors:  Zapporah T Young; Sue Ann Mok; Jason E Gestwicki
Journal:  Cold Spring Harb Perspect Med       Date:  2018-01-02       Impact factor: 6.915

4.  Protein profiling of isolated uterine AA amyloidosis causing fetal death in goats.

Authors:  Patricia M Gaffney; Bradd Barr; Joan D Rowe; Cyrus Bett; Ioannis Drygiannakis; Federico Giannitti; Margarita Trejo; Majid Ghassemian; Patrice Martin; Eliezer Masliah; Christina J Sigurdson
Journal:  FASEB J       Date:  2014-11-24       Impact factor: 5.191

5.  Alzheimer disease: chaperone protein clusterin is involved in amyloid-β-associated entorhinal atrophy in early AD.

Authors:  Hemi Malkki
Journal:  Nat Rev Neurol       Date:  2014-01-21       Impact factor: 42.937

6.  From Analysis of Ischemic Mouse Brain Proteome to Identification of Human Serum Clusterin as a Potential Biomarker for Severity of Acute Ischemic Stroke.

Authors:  Hailong Song; Hui Zhou; Zhe Qu; Jie Hou; Weilong Chen; Weiwu Cai; Qiong Cheng; Dennis Y Chuang; Shanyan Chen; Shuwei Li; Jilong Li; Jianlin Cheng; C Michael Greenlief; Yuan Lu; Agnes Simonyi; Grace Y Sun; Chenghan Wu; Jiankun Cui; Zezong Gu
Journal:  Transl Stroke Res       Date:  2018-11-21       Impact factor: 6.829

7.  Clusterin Binds to Aβ1-42 Oligomers with High Affinity and Interferes with Peptide Aggregation by Inhibiting Primary and Secondary Nucleation.

Authors:  Marten Beeg; Matteo Stravalaci; Margherita Romeo; Arianna Dorotea Carrá; Alfredo Cagnotto; Alessandro Rossi; Luisa Diomede; Mario Salmona; Marco Gobbi
Journal:  J Biol Chem       Date:  2016-02-16       Impact factor: 5.157

Review 8.  Microglial malfunction: the third rail in the development of Alzheimer's disease.

Authors:  Siddhita D Mhatre; Connie A Tsai; Amanda J Rubin; Michelle L James; Katrin I Andreasson
Journal:  Trends Neurosci       Date:  2015-10       Impact factor: 13.837

9.  A potential endophenotype for Alzheimer's disease: cerebrospinal fluid clusterin.

Authors:  Yuetiva Deming; Jian Xia; Yefei Cai; Jenny Lord; Peter Holmans; Sarah Bertelsen; David Holtzman; John C Morris; Kelly Bales; Eve H Pickering; John Kauwe; Alison Goate; Carlos Cruchaga
Journal:  Neurobiol Aging       Date:  2015-09-25       Impact factor: 4.673

10.  Association between clusterin concentration and dementia: a systematic review and meta-analysis.

Authors:  Caiping Yang; Hai Wang; Chaojiu Li; Huiyan Niu; Shunkui Luo; Xingzhi Guo
Journal:  Metab Brain Dis       Date:  2018-10-05       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.